pharmacy

Galvecta Plus SpecificationRequires Prescription (YES/NO)YesGenericsVildagliptin + Metformin HClUsed ForDiabetesHow it worksThe administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide). Metformin HCl decreases hepatic glucose production through inhibition of gluconeogenesis and glycogenolysis, decrease intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.Galvecta Plus Usage And SafetyDosageVildagliptin + Metformin HClSide EffectsHypoglycemia, tremor, headache, dizziness & nausea , Fatigue , Hypoglycemia, dizziness, tremor, hyperhidrosis & asthenia , Decreased blood glucose, headache, chills, nausea, gastro-esophageal reflux disease , diarrhea & flatulence.Drug InteractionsThiazides, corticosteroids, thyroid products and sympathomimetics , Furosemide , Nifedipine , Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) , estrogens, oral contraceptives, phenytoin, nicotinic acid , alcohol.IndicationVildagliptin + Metformin HCl is indicated for the treatment of patients with Type 2 diabetes mellitus (T2DM). Vildagliptin + Metformin HCl is indicated as an adjunct to diet and exercise to improve glycemic control in patients whose diabetes is not adequately controlled on metformin HCl alone or who are already treated with the combination of vildagliptin and metformin HCl, as separate tablets.When not to UseVildagliptin + Metformin HCl combination is contraindicated in: - Patients with known hypersensitivity to vildagliptin or metformin HCl or to any excipient of the product. - Diabetic ketoacidosis or diabetic pre-coma.Galvecta Plus PrecautionsPrecautionVildagliptin + Metformin HCl combination is not substitute for insulin-requiring patients and should not be used in patients with type 1 diabetes.Galvecta Plus WarningsWarning 1In diabetic patient, monitoring for skin disorders, such as blistering or ulceration, is recommended.Warning 2Use of vildagliptin has been associated with a risk of developing acute pancreatitis. If pancreatitis is suspected, vildagliptin should be discontinued and if acute pancreatitis is confirmed, vildagliptin should not be restarted. Caution should be exercised in patients with a history of acute pancreatitis.Warning 3Treatment with metformin should be discontinued 48 hours before elective surgery with general anesthesia and should not usually be resumed earlier than 48 hours afterwards.Galvecta Plus Additional InformationPregnancy categoryAlways consult your physician before using any medicine.Storage (YES/NO)Store this medicine at room temperature, away from direct light and heat.

Galvecta Tablets SpecificationRequires Prescription (YES/NO)YesGenericsVildagliptinUsed ForDiabetesHow it worksThe administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).Galvecta Tablets Usage And SafetyDosageVildagliptinSide EffectsMonotherapy Common: Dizziness. Uncommon: Hypoglycemia, headache, edema peripheral, constipation & arthralgia. Very Rare: Upper respiratory tract infection & nasopharyngitis. Combination with Metformin Common: Hypoglycemia, tremor, headache, dizziness & nausea. Uncommon: Fatigue. Combination with Sulfonylurea Common: Hypoglycemia, tremor, headache, dizziness & asthenia. Uncommon: Constipation. Very Rare: Nasopharyngitis. Combination with Thiazolidinedione Common: Weight increase & edema peripheral. Uncommon: Hypoglycemia, headache & asthenia. Combination with Metformin and Sulfonylurea Common: Hypoglycemia, dizziness, tremor, hyperhidrosis & asthenia. Combination with Insulin Common: Decreased blood glucose, headache, chills, nausea, gastroesophageal reflux disease. Uncommon: Diarrhea & flatulence.Drug InteractionsVildagliptin has a low potential for interactions with co-administered medicinal products. Since vildagliptin is not a cytochrome P (CYP) 450 enzyme substrate and does not inhibit or induce CYP450 enzymes, it isnot likely to interact with active substances that are substrates, inhibitors or inducers of these enzymes. As with other oral antidiabetic medicinal products the hypoglycemic effect of vildagliptin may be reduced by certain active substances, including thiazides, corticosteroids, thyroid products and sympathomimetics.IndicationVildagliptin is indicated for the treatment of type 2 diabetes mellitus in adults:As monotherapy - In patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.As dual oral therapy in combination with - Metformin, in patients with insufficient glycemic control despite maximal tolerated dose of monotherapy with metformin.- Sulfonylurea, in patients with insufficient glycemic control despite maximal tolerated dose of a sulfonylurea and for whom metformin is inappropriate due to contraindications or intolerance.- Thiazolidinedione, in patients with insufficient glycemic control and for whom the use of a thiazolidinedione is appropriate. As triple oral therapy in combination with- Sulfonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycemic control.Vildagliptin is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycemic control.When not to UseVildagliptin is contraindicated in patients with known hypersensitivity to vildagliptin or to any excipient of the product.Galvecta Tablets PrecautionsPrecautionRare cases of hepatic dysfunction (including hepatitis) have been reported. Liver function tests should be performed prior to the initiation of treatment. Liver function should be monitored during treatment with vildagliptin at three-month intervals during the first year and periodically thereafter. Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue vildagliptin.Galvecta Tablets WarningsWarning 1Vildagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.Warning 2In diabetic patient, monitoring for skin disorders, such as blistering or ulceration, is recommended.Warning 3Use of vildagliptin has been associated with a risk of developing acute pancreatitis. If pancreatitis is suspected, vildagliptin should be discontinued and if acute pancreatitis is confirmed, vildagliptin should not be restarted. Caution should be exercised in patients with a history of acute pancreatitis.Galvecta Tablets Additional InformationPregnancy categoryAlways consult your physician before using any medicine.Storage (YES/NO)Store this medicine at room temperature, away from direct light and heat.

GALVUS 50 MG ( VILDAGLIPTIN ) 28 TABLETS

GALVUS 50MG